Indaptus Therapeutics (INDP)

• Market cap: $2.52M
• 1 day: -11.63%
• 5 days: -10.59%
• 1 month: -67.98%
• 3 months: -73.91%
• 6 months: -89.97%
• Year to date: -90.47%
• 1 year: -94.78%
• 5 years: -99.65%
• 10 years: -99.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Employees: 7

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0.16% less ownership

Funds ownership: 0.16% [Q1] → 0% (-0.16%) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

69% less funds holding

Funds holding: 16 [Q1] → 5 (-11) [Q2]

92% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 12

99% less capital invested

Capital invested by funds: $354K [Q1] → $3.23K (-$350K) [Q2]